信立泰:2025一季报净利润2亿 同比下降0%

Financial Data and Indicators - The basic earnings per share for Q1 2025 remained unchanged at 0.1800 CNY compared to Q1 2024, while it decreased from 0.1900 CNY in Q1 2023 [1] - The net asset per share increased by 8.4% to 8 CNY in Q1 2025 from 7.38 CNY in Q1 2024 [1] - The operating revenue for Q1 2025 was 10.62 billion CNY, a decrease of 2.66% from 10.91 billion CNY in Q1 2024, but an increase from 8.88 billion CNY in Q1 2023 [1] - The net profit for Q1 2025 was 2 billion CNY, unchanged from Q1 2024, but down from 2.11 billion CNY in Q1 2023 [1] - The return on equity (ROE) decreased by 8.1% to 2.27% in Q1 2025 from 2.47% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 76,343.2 million shares, accounting for 68.49% of the circulating shares, with a decrease of 456.69 million shares compared to the previous period [1] - The largest shareholder, Xinlitai Pharmaceutical Co., Ltd., holds 63,527.94 million shares, representing 57.00% of the total share capital, with no change [2] - The second largest shareholder, Shenzhen Xinlitai Pharmaceutical Co., Ltd. - Third Employee Stock Ownership Plan, holds 2,345.75 million shares, accounting for 2.10%, with no change [2] Dividend Distribution - The company has decided not to distribute dividends or transfer shares in this period [2]